Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
Rigetti has technical credibility and a proposed $100M federal quantum award, but the investment case still hinges on revenue scale, cash burn, fidelity, and system roadmap execution.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
D-Wave has one of the clearest customer-demand signals in quantum after record bookings, but the Q1 revenue base remained small and losses expanded.
OpenInfleqtion has a clean quantum identity, record Q1 revenue, and a proposed $100M federal tailwind, but the business still needs revenue scale and operating-loss discipline.
OpenGlobalFoundries has the largest public-market quantum foundry angle in this batch, but investors still need proof that the proposed CHIPS funding and customer engagements become durable demand instead of a one-day headline.
OpenAEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matt
OpenAdaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.
OpenADCT already sells ZYNLONTA, but the story is not solved by having revenue. The next question is whether the 2026 lymphoma data can widen the drug's role before cash burn, royalties, debt, and dilution take the lead.
OpenAdagene is trying to turn SAFEbody antibody masking into a broader immuno-oncology platform. The hook is muzastotug's early dose-dependent signal; the catch is that randomized proof, partner execution, and financing still decide the stock.
OpenActuate has a company-defining elraglusib Phase 2 pancreatic-cancer survival signal and a new oral IND, but the same source set shows no product revenue, going-concern disclosure, and a need for capital beyond July 2026.
OpenOfficial-source baseline for Ascentage Pharma using SEC submissions, FY2025 Form 20-F, SEC companyfacts, company-filed FY2025 results releases, ASCO 2026 update, annual meeting materials, and oncology peer filings.
OpenTag facets appear after tag usage counts are rebuilt.